Brought to you by 
Dainippon to develop Intercept’s obeticholic acid for Asian markets; Intercept regains certain rights
14 Feb 2018
Executive Summary
Intercept Pharmaceuticals Inc. (hepatic and metabolic diseases) has licensed Sumitomo Chemical Co.’s drug subsidiary Dainippon Sumitomo Pharma Co. Ltd. rights to exclusively develop and market its obeticholic acid (INT747; formerly 6ECDCA) in Japan and China (with an exclusive option to add other Asian countries including Korea and Taiwan). OCA is in Phase II for primary biliary cirrhosis, nonalcoholic steatohepatitis, and primary sclerosing cholangitis. Dainippon also has the option to investigate other indications.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Dainippon to develop Intercept’s obeticholic acid for Asian markets; Intercept regains certain rights
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice